A characteristic of patients cohort
| MIS ID . | Sex . | Age Dx, mo . | Age Tx, mo . | Organs involved . | LoT . | Previous therapy . | DAS, points . | DAS after vemu, points . | cfDNA load initially, % . | cfDNA load vemu cess, % . | cfDNA load therapy end, % . | MP BRAF load initially, % . | MP load vemu cess, % . | MP BRAF load therapy end, % . | Relapse . | EFS/time to relapse, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 132056 | F | 15 | 27 | RO, skin | 2 | VBL + PRE | 20 | 2 | 14.08 | <LoD | 0.5 | 4.84 | <LoD | <LoD | No | 45 |
| 147958 | F | 0 | 4 | RO, skin, lungs | 1 | No | 8 | 0 | 1.41 | <LoD | n/d | <LoD | <LoD | n/d | Yes (skin) | 1 |
| 189102 | F | 15 | 17 | RO, skin | 1 | No | 16 | 0 | 15.88 | <LoD | <LoD | 0.87 | <LoD | 0.01 | No | 21 |
| 159833 | F | 22 | 25 | RO, skin | 1 | No | 15 | 0 | 5.25 | 0.33 | 0.24 | 0.6 | <LoD | <LoD | No | 34 |
| 153888 | M | 19 | 25 | RO, skin, lungs | 2 | VBL + PRED | 6 | 0 | 5.29 | <LoD | 0.86 | 0.1 | 0.03 | 0.07 | Yes (bone) | 8 |
| 187463 | F | 14 | 17 | RO | 1 | No | 13 | 0 | 12.69 | <LoD | <LoD | 0.79 | <LoD | <LoD | No | 25 |
| 190889 | M | 1 | 31 | RO, skin, MF bones | 4 | VBL + PRED, VBL + PRED + VP16, VCR/Ara-C/PRED | 8 | 2 | 3.48 | 0.51 | 1.55 | 1.13 | 0.02 | 0.03 | No | 18 |
| 186934 | M | 9 | 15 | RO, skin | 2 | VBL + PRED | 19 | 2 | 3.66 | 0.20 | 0.54 | n/d | 0.06 | 0.05 | No | 21 |
| 202807 | M | 5 | 7 | RO, MF bones, skin, l/n, lungs | 1 | No | 16 | 2 | 14.80 | 0.94 | 0.16 | 0.68 | <LoD | <LoD | No | 15 |
| 181102 | M | 3 | 8 | RO, skin | 1 | No | 16 | 0 | 12.41 | 1.18 | 2.33 | 1.81 | 0.20 | 1.03 | Yes (RO+) | 2 |
| 116953 | F | 10 | 39 | RO, MF bones, DI, skin | 3 | VBL + PRED, VCR/Ara-C/PRED | 10 | 2 | 30.91 | 0.34 | <LoD | 1.77 | <LoD | <LoD | No | 23 |
| 188277 | F | 10 | 15 | RO, MF bones | 2 | VBL + PRED | 13 | 0 | 8.32 | 0.12 | <LoD | 3.49 | <LoD | <LoD | No | 20 |
| 209525 | M | 4 | 8 | RO, MF bones, skin, l/n, gut | 2 | VBL + PRED | 13 | 2 | 12.7 | 0.39 | <LoD | n/d | 0.05 | <LoD | No | 10 |
| 23245 | F | 43 | 107 | MF bones, skin | 3 | VBL + PRED, VCR/Ara-C/PRED | 5 | 1 | 0.14 | n/d | n/d | <LoD | n/d | n/d | No | 29 |
| 71021 | M | 18 | 38 | MF bones, skin | 3 | VBL + PRED, VCR/Ara-C/PRED | 6 | 0 | 8.60 | 0.56 | <LoD | 0.98 | 0.10 | <LoD | No | 40 |
| 50799 | M | 35 | 73 | MF bones, skin | 3 | VBL + PRED, VCR/Ara-C/PRED | 4 | 0 | <LoD | <LoD | <LoD | <LoD | <LoD | <LoD | No | 20 |
| 143428 | F | 28 | 76 | MF bones, skin, lungs, l/n | 3 | VBL + PRED, VCR/Ara-C/PRED | 6 | 1 | 3.61 | 0.07 | 0.42 | 0.61 | 0.02 | 0.02 | No | 23 |
| 76298 | F | 20 | 51 | MF bones, skin, l/n, DI | 3 | VBL + PRED, VCR/Ara-C/PRED | 1 | 0 | 1.10 | <LoD | <LoD | 0.10 | <LoD | 0.02 | No | 33 |
| 127734 | M | 18 | 37 | MF bones, skin | 4 | VBL + PRED, VCR/Ara-C/PRED, 2-CdA | 3 | 0 | 1.43 | <LoD | <LoD | <LoD | <LoD | <LoD | Yes (bone) | 2 |
| MIS ID . | Sex . | Age Dx, mo . | Age Tx, mo . | Organs involved . | LoT . | Previous therapy . | DAS, points . | DAS after vemu, points . | cfDNA load initially, % . | cfDNA load vemu cess, % . | cfDNA load therapy end, % . | MP BRAF load initially, % . | MP load vemu cess, % . | MP BRAF load therapy end, % . | Relapse . | EFS/time to relapse, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 132056 | F | 15 | 27 | RO, skin | 2 | VBL + PRE | 20 | 2 | 14.08 | <LoD | 0.5 | 4.84 | <LoD | <LoD | No | 45 |
| 147958 | F | 0 | 4 | RO, skin, lungs | 1 | No | 8 | 0 | 1.41 | <LoD | n/d | <LoD | <LoD | n/d | Yes (skin) | 1 |
| 189102 | F | 15 | 17 | RO, skin | 1 | No | 16 | 0 | 15.88 | <LoD | <LoD | 0.87 | <LoD | 0.01 | No | 21 |
| 159833 | F | 22 | 25 | RO, skin | 1 | No | 15 | 0 | 5.25 | 0.33 | 0.24 | 0.6 | <LoD | <LoD | No | 34 |
| 153888 | M | 19 | 25 | RO, skin, lungs | 2 | VBL + PRED | 6 | 0 | 5.29 | <LoD | 0.86 | 0.1 | 0.03 | 0.07 | Yes (bone) | 8 |
| 187463 | F | 14 | 17 | RO | 1 | No | 13 | 0 | 12.69 | <LoD | <LoD | 0.79 | <LoD | <LoD | No | 25 |
| 190889 | M | 1 | 31 | RO, skin, MF bones | 4 | VBL + PRED, VBL + PRED + VP16, VCR/Ara-C/PRED | 8 | 2 | 3.48 | 0.51 | 1.55 | 1.13 | 0.02 | 0.03 | No | 18 |
| 186934 | M | 9 | 15 | RO, skin | 2 | VBL + PRED | 19 | 2 | 3.66 | 0.20 | 0.54 | n/d | 0.06 | 0.05 | No | 21 |
| 202807 | M | 5 | 7 | RO, MF bones, skin, l/n, lungs | 1 | No | 16 | 2 | 14.80 | 0.94 | 0.16 | 0.68 | <LoD | <LoD | No | 15 |
| 181102 | M | 3 | 8 | RO, skin | 1 | No | 16 | 0 | 12.41 | 1.18 | 2.33 | 1.81 | 0.20 | 1.03 | Yes (RO+) | 2 |
| 116953 | F | 10 | 39 | RO, MF bones, DI, skin | 3 | VBL + PRED, VCR/Ara-C/PRED | 10 | 2 | 30.91 | 0.34 | <LoD | 1.77 | <LoD | <LoD | No | 23 |
| 188277 | F | 10 | 15 | RO, MF bones | 2 | VBL + PRED | 13 | 0 | 8.32 | 0.12 | <LoD | 3.49 | <LoD | <LoD | No | 20 |
| 209525 | M | 4 | 8 | RO, MF bones, skin, l/n, gut | 2 | VBL + PRED | 13 | 2 | 12.7 | 0.39 | <LoD | n/d | 0.05 | <LoD | No | 10 |
| 23245 | F | 43 | 107 | MF bones, skin | 3 | VBL + PRED, VCR/Ara-C/PRED | 5 | 1 | 0.14 | n/d | n/d | <LoD | n/d | n/d | No | 29 |
| 71021 | M | 18 | 38 | MF bones, skin | 3 | VBL + PRED, VCR/Ara-C/PRED | 6 | 0 | 8.60 | 0.56 | <LoD | 0.98 | 0.10 | <LoD | No | 40 |
| 50799 | M | 35 | 73 | MF bones, skin | 3 | VBL + PRED, VCR/Ara-C/PRED | 4 | 0 | <LoD | <LoD | <LoD | <LoD | <LoD | <LoD | No | 20 |
| 143428 | F | 28 | 76 | MF bones, skin, lungs, l/n | 3 | VBL + PRED, VCR/Ara-C/PRED | 6 | 1 | 3.61 | 0.07 | 0.42 | 0.61 | 0.02 | 0.02 | No | 23 |
| 76298 | F | 20 | 51 | MF bones, skin, l/n, DI | 3 | VBL + PRED, VCR/Ara-C/PRED | 1 | 0 | 1.10 | <LoD | <LoD | 0.10 | <LoD | 0.02 | No | 33 |
| 127734 | M | 18 | 37 | MF bones, skin | 4 | VBL + PRED, VCR/Ara-C/PRED, 2-CdA | 3 | 0 | 1.43 | <LoD | <LoD | <LoD | <LoD | <LoD | Yes (bone) | 2 |
Age Dx, age at diagnosis; Age Tx, age at protocol start; DI, diabetes insipidus; F, female; l/n, lymph nodes; <LoD, below level of detection; LoT, line of therapy; M, male; MF, multifocal; MP, myeloid progenitors; n/d, no data; PRED, prednisone; VBL, vinblastine; VP-16, etoposide.